Abstract
Rapid Clearance of Erythrodermic Psoriasis with Acitretin in an Unstable Case of Psoriasis under Treatment with Secukinumab
Highlights
S Erythrodermic Psoriasis (EP) is a rare, severe and disabling form of psoriasis in children and adults with an estimated prevalence among psoriatic patients ranging from 1%-2.25% [1]
Is not well understood; numerous studies advocate that the disease is associated with a predominantly T helper 2 (Th2)
The triggers of erythrodermic psoriasis are an abrupt extraction of anti-psoriatic drugs such as methotrexate and topical steroids, systemic illness (e.g. HIV, infections), ultraviolet burns, drug reaction, abuse of alcohol, and emotional stress [1,2]
Summary
(baseline PASI score 29.0), without concomitant arthritis, and was Erythrodermic Psoriasis (EP) is a rare, severe and disabling form of psoriasis in children and adults with an estimated prevalence among psoriatic patients ranging from 1%-2.25% [1]. This subtype successfully treated with secukinumab in the last year (PASI score 0). He did not have any other new drug exposures and did not use topical medications other than moisturizers, in the last 3 months of psoriasis presents with distinct clinical characteristics, which include a diffuse erythema involving at least 75% of the body surface area. The patient remains clear of psoriasis lesions with ongoing acitretin therapy after 16 weeks, with a tapering of acitretin while transitioning to the precedent biologic agent
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.